Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

CORAL GABLES, Fla., April 4, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022. The conference is being held Monday, April 4, 2022, through Wednesday, April 6, 2022, in Oxford, United Kingdom, and online.

The poster presentations will highlight the recently completed human abuse potential studies evaluating REL-1017 versus ketamine and oxycodone. The oral presentation will highlight data from the completed Phase 2 study of REL-1017 as adjunctive treatment for patients with major depressive disorder, as well as preclinical data characterizing the product candidate's mechanism of action. Further details of the presentations are as follows:

Title: No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant

Title: No meaningful abuse potential in recreational opioid users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant 

Live Q&A: Tuesday, April 5, 2022, from 9:00am - 9:30am ET

Title: REL-1017 (esmethadone hydrochloride), an NMDAR antagonist for the treatment of Major Depressive Disorder 

Date: Wednesday, April 6^th, 2022

Time: 10:30am - 11am ET

The oral presentation is only available to registered conference attendees. Further information on the conference can be found here: https://web.cvent.com/event/80e7b288-cccf-4b92-978a-3da3a6b389a5/summary.

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated robust, rapid, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
917-679-9282
tim@lifesciadvisors.com 

Media Inquiries:
FischTank PR
relmada@fischtankpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-data-at-the-ketamine--related-compounds-international-hybrid-conference-2022-301516645.html

SOURCE Relmada Therapeutics, Inc.